ACT-333679

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2018
02420102018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Prostacyclin (PGI2) receptor (IP receptor) agonists, which are indicated for the treatment of pulmonary arterial hypertension… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
PURPOSE Selexipag is a new orally available nonprostanoid prostacyclin receptor agonist for the treatment of pulmonary arterial… (More)
Is this relevant?
2015
2015
AIMS This study investigated the effect of a fixed dose combination of lopinavir/ritonavir on the pharmacokinetics (PK) of… (More)
Is this relevant?
2015
2015
PURPOSE Targeting the prostacyclin pathway is an effective treatment option for pulmonary arterial hypertension (PAH). Patients… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2015
2015
OBJECTIVE Selexipag is a novel, oral, selective prostacyclin (PGI2) receptor agonist in clinical development for the treatment of… (More)
Is this relevant?
2015
2015
The effects of selexipag and its active metabolite ACT-333679 on cardiac repolarization were assessed in a thorough QT study as… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2014
2014
OBJECTIVE The objective of this study was to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag… (More)
Is this relevant?
2013
2013
The prostacyclin (IP) receptor agonists, treprostinil, iloprost and the selexipag metabolite, MRE-269 (ACT-333679) were evaluated… (More)
Is this relevant?
2012
2012
{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (ACT-333679) is the main metabolite of the selective… (More)
Is this relevant?
2010
2010
Selexipag [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide] is an orally available… (More)
  • figure 1
  • table 1
  • figure 3
  • figure 5
  • figure 6
Is this relevant?